2024³â 12¿ù 29ÀÏ ÀÏ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýÈ°

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óÇ°

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb, the Company¡¯s novel transgenic chicken platform launchen 2023 that generates fully human and stabilized sdAbs
´º½ºÀÏÀÚ: 2024-06-11

EMERYVILLE, CALIF. -- OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies.

sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks for antibody discovery. While most other vertebrates use the standard heterodimeric IgG structure due to the pairing of heavy and light chains and do not produce sdAb format immunoglobulins, OmniAb’s scientific team led this study to investigate if chickens can support an immune repertoire based upon a heavy chain-only scaffold.

“Our team’s published data provided the foundational work supporting the feasibility of the Company’s next-generation transgenic chicken OmnidAb that produces fully human stabilized sdAbs. Unique physical properties of sdAbs can be leveraged for evolving fields of antibody discovery, including alternate routes of administration, diagnostic applications and therapeutic approaches that are being explored by many of our partners,” said Matt Foehr, Chief Executive Officer of OmniAb. “We currently have 80 partners leveraging OmniAb’s various platform technologies and accessing OmniAb antibodies, spanning major geographies and ranging from multinational big pharmas to venture-backed startups and leading academics.”

“Our truncated light chain chickens are designed to produce heavy (H) chain-only antibodies by deleting the light (L) chain variable region and maintaining only the constant region to serve as a chaperone for antibody secretion from the cell. We confirmed in this published study that the H chain variable region functions autonomously as a single domain without further engineering, producing sdAbs with favorable biophysical properties and antigen recognition profiles,” said Philip Leighton, Ph.D., Fellow of Molecular Biology of OmniAb. “Truncated L chain design successfully supported sdAb development and expression in chickens, and we are delighted that this work enabled the successful launch of OmnidAb.”



 Àüü´º½º¸ñ·ÏÀ¸·Î

SES¡¯s Seventh and Eighth O3b mPOWER Satellites Successfully Launched, Bolstering MEO Constellation
Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape
Biocodex Strengthens Supply Chain Resilience with Kinaxis
PHC Live Cell Metabolic Analyzer (LiCellMo) Receives 2024 Innovation Award from The Analytical Scientist
IRIS2 lifts off as European Commission and SpaceRISE sign contract in Brussels
HistoSonics Edison¢ç Histotripsy System Treats First Pancreatic Tumor Patients in GANNON Trial
Novotech Named a Fierce CRO Award Winner in the Excellence

 

SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Again...
The Next Gen of AI Awaits, GIGABYTE Sets the Benchmark for HPC at CES ...
SpaceRISE Signs Concession Contract to Deliver Europe¡¯s IRIS©÷ Connec...
Boomi Boosts Data Management Capabilities With Acquisition of Modern D...
Korean Robotaxi Startup Sonnet.AI Secures Level 4 Autonomous Shuttles ...
KIOXIA NVMe SSD Cryptographic Module Achieves FIPS 140-3 Level 2 Valid...
CHMP Recommends Approval of Galderma¡¯s Nemolizumab for Moderate-to-Se...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚÇ¥±â 'ãæÚ¤ó¢'
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á
¾Ë¶ã°Ç¼³, »óÇ¥µî·Ï ¿Ï·á
Á¸Â÷´åÄÄ, ±Û²Ã º¯°æ »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇÑ°è¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, Æѽº 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..